Phase 3
Completed N=53
Opioid Analgesic Reduction Study (OARS) - Pilot
Post Operative Pain
Source: ClinicalTrials.gov NCT05283499 ↗
Enrolled (actual)
53
Serious AEs
0.0%
Results posted
Jul 2022
Primary outcomePrimary: Pain Level — 5.67; 4.09 score on a scale
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this study is to test protocols being developed for the conduct of a large sale multi-site clinical trial which will compare opioids to non-opioids for managing post-surgical impacted 3rd molar extraction pain.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain Level |
4.00; 2.74 | — |
| PRIMARY Pain Level |
4.00; 2.74 | — |
| PRIMARY Pain Level |
4.00; 2.74 | — |
| SECONDARY Sleep Quality |
4.38; 2.89 | — |
| SECONDARY Sleep Quality |
4.38; 2.89 | — |
| SECONDARY Sleep Quality |
4.38; 2.89 | — |
| SECONDARY Sleep Quality |
4.38; 2.89 | — |
| SECONDARY Pain Interference Scale (Patient Report Outcomes Measurement Information System - PROMIS 6b ) |
13.74; 11.01 | — |
| SECONDARY Pain Interference Scale (Patient Report Outcomes Measurement Information System - PROMIS 6b ) |
13.74; 11.01 | — |
| SECONDARY Pain Interference Scale (Patient Report Outcomes Measurement Information System - PROMIS 6b ) |
13.74; 11.01 | — |
| SECONDARY Pain Interference Scale (Patient Report Outcomes Measurement Information System - PROMIS 6b ) |
13.74; 11.01 | — |
| SECONDARY Overall Satisfaction |
2.1; 1.7 | — |
Eligibility Criteria
Inclusion Criteria
- Adult men and non-pregnant women who are at least 18 years of age, who are able to refrain from driving or operating heavy machinery while taking the study medication will be able to participate.
- Subjects who are English speaking and are able to provide consent will be considered.
- Subjects must be in generally good health and able to take ibuprofen, paracetamol (acetaminophen), and hydrocodone.
Exclusion Criteria
Subjects who self-report the following history will be excluded from participating:
- Individual under the age of 18
- History of gastrointestinal bleeding and/or peptic ulcer
- History of renal disease (excluding kidney stones)
- History of hepatic disease
- History of bleeding disorder
- History of respiratory depression
- Any prior respiratory effect of an opioid or other anesthetic drug that required respiratory support postoperatively
- Active or untreated asthma
- History of known allergic reaction to ibuprofen, acetaminophen, hydrocodone, and/or anesthesia
- Currently taking any of the following medications:
- CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), which may increase plasma concentrations of hydrocodone bitartrate and acetaminophen and prolong opioid adverse reactions, and which may cause potentially fatal respiratory depression
- CNS depressants.
- Consumes 3 or more alcoholic drinks every day and/or has a history of alcoholism
- History of drug or alcohol abuse (excludes marijuana use)
- Family history of drug or alcohol abuse in a first degree relative
- Has had one or more opioid prescription filled within the past 6 months
- Currently pregnant or lactating
Patients would also be excluded due to any additional criteria that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study which includes:
- Prior participation in this study
- Inability or refusal to provide informed consent
Data sourced from ClinicalTrials.gov (NCT05283499). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.